IMNN Imunon, Inc. Return on Gross Profit

Official company branding of imunon.com (IMNN)

Risks of DNA synthesis capacity downtime are mitigated by Imunon, Inc. (IMNN) through an innovative approach to cancer therapy and strict adherence to ESG standards. The gross margin trend, based on chart data from GURU.Markets, indicates a support level where the 0.00 indicator expresses the state of the metric. Production efficiency is combined with advanced genetic engineering methods and transparent corporate compliance.

IMNN - Imunon, Inc. Gross Profitability over the range 04/28/2023 - 11/20/2026

Analytical breakdowns and data insights for company Imunon, Inc. (IMNN)

- current quotes and average value forecast:
Fundamental valuation:Imunon, Inc.
Brand item of Celsion Corporation

The investment appeal of Imunon, Inc. (IMNN) is based on unique PlasmID patents and high barriers to entry within the DNA immunotherapy sector. This indicator determines the portion of revenue remaining after covering direct production costs, allowing for an assessment of the efficiency of intellectual property monetization. By analyzing gross margin stability, an investor can differentiate real growth in operational efficiency from temporary market fluctuations, confirming the fundamental resilience of the business.

Direct competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|Gross Profit Margin REGENXBIO Inc. RGNX|Gross Profitability Solid Biosciences (SLDB)|Ocugen Corp - Gross Return on Sales|Gross Profitability Pacific Biosciences PACB|Gross Profit Ratio BNTC (Benitec)|Design Corp - Gross Margin|Rocket Pharmaceuticals - Gross Profit Ratio|Gross Return on Sales 4D Molecular Therapeutics, Inc.|Gross Profit Margin Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Gross Margin|Gross Profit Margin Editas EDIT|Gross Margin SLN|ProQR Therapeutics - Gross Return on Sales|Gross Margin CDXS (Codexis, Inc.)|SGMO: Gross Return on Sales|Nautilus Biotechnology - Gross Margin|Gross Profit Rate MGX (Metagenomi, Inc)|DTIL: Gross Margin|GBIO: Gross Profit Ratio|Gross Profitability Boundless Bio Inc.|Return on Gross Profit Exicure (XCUR)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability